gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin readi file hemophilia gt
highlight week may june unrat report interim data
phase trial gene therapi gt valoctocogen roxaparvovec valrox hemophilia
patient cohort phase studi achiev pre-specifi criteria factor
fviii level intern unit per decilit iu/dl greater week post-treat compani plan
meet fda ema review data announc time regulatori file
amicu neutral announc expans gt collabor wilson lab univers
pennsylvania agreement expand current collabor lysosom disord includ new
indic well addit rare diseas indic term agreement amicu invest mm
per year year discoveri research program upenn gene therapi program buy present
interim data phase trial person cancer vaccin american societi
clinic oncolog annual meet chicago well-toler dose dose-limit
toxic grade advers event seriou advers event report addit immunogen
data patient avail deeper immunogen respons character data receiv highest
dose show cell respons mhc class antigen vaccin support
use person cancer vaccin elicit immun respons patient individu tumor mutat
look forward june june may june american societi clinic oncolog
host annual meet chicago program includ repres unrat
neutral unrat genet medicin compani june triplet repeat
disord confer neurodegener triplet repeat diseas molecular pathogenesi ration
therapeut take place lucca itali agenda featur present uniqur buy chardan top
pick neutral unrat june
convent take place philadelphia agenda featur repres numer compani interest
spark neutral strand privat buy vbl neutral
weekli price move vivo genet medicin aav srna mrna vivo gene edit
 mrna mm vivo gene edit mm contributor buy mm
upcom chardan genet medicin event contact chardan rsvp
june network recept host chardan allanc regen medicin philadelphia
buy inflect point feedback roadshow may amusa
pleas refer import disclosur inform regul analyst certif found page report
particip seri chardan-host investor meet new york may investor focu
opportun intellectu properti ip surround pipelin highlight left
meet belief multipl asset intern partner program name wet
mp ii program zolgensma hemophilia partner program may drive share price appreci
also believ increas likelihood captur valu ip like use
elsewher trial includ duchenn muscular dystrophi market unrat sarepta
 uncertainti around zolgensma approv may caus recent share price weak issu
 pipelin show high rate success progress aim
note follow key theme roadshow
resolv given announc approv may
ind per year intern pipelin wave partner opportun make real progress
 express optim hemophilia asset takeda unrat and/or bayer unrat
may gener data later year suggest interest gt asset hand lead compani
 robustli address number common market misunderstand wet
show optim data gener far
 may aggress defend intellectu properti estat onward
buy cso appoint signal slow crispr exec exit may livshit
intellia announc appoint laura sepp-lorenzino phd execut vice presid
chief scientif offic dr sepp-lorenzino previous held leadership role biopharma compani includ alnylam
buy see particularli relev given parallel compani pipelin
transthyretin amyloidosi primari hyperoxaluria well use lipid-nanoparticl lnp technolog deliv
crispr/ca rna intellia sirna therapeut alnylam liver
januari research note trend execut turnover/departur helm crispr gene
edit compani occur cours note chang occur
compani transit preclinical- clinical-stag compani therefor see intellia appoint dr sepp-
lorenzino earli posit signal compani advanc vivo ex vivo program
buy data june amusa
present interim phase data mrna person cancer vaccin
patient resect adjuv unresect advanc solid tumor see poster slide
report given alon combin pembrolizumab keytruda pembro elicit
neoantigen-specif t-cell respons associ clinic activ patient well-
toler produc vaccine-rel sae
highlight evid neoantigen-specif t-cell respons seen patient avail
data complet respons cr partial respons pr seen unresect patient
adjuv patient diseas free week
data us build upon prior data demonstr degre cell respons antigen provid
vaccin robust higher vaccin dose safeti make clear argument
pembro add-on efficaci seen futur trial
genet medicin news may june
fred hutchinson publish crispr nanoformul use gold nanoparticl may
tng fp unrat announc complet enrol phase ii trial combo tx nsclc may
qure buy publish data efficaci gt hemb despit pre-exist nab may
sln gb unrat announc collabor genom england privat novel genet target may
oxb gb unrat announc mm share invest novo hold may
unrat announc follow-up data phase i/ii studi valrox hemophilia may
provid interim data phase i/ii trial gt valrox
patient receiv dose vg/kg valrox patient receiv dose vg/kg data
present includ follow-up data high dose cohort follow-up data low dose cohort
high dose cohort result show median annual bleed rate abr mean abr year post-
treatment reduct baselin mean median fviii level iu/dl iu/dl respect
end year compar iu/dl iu/dl respect end year base
page
conclus level fviii express reach plateau manag comment conserv
statist model anticip bleed control maintain least eight year gene transfer
low dose cohort result show median abr mean abr year post-treat
reduct baselin mean median fviii level iu/dl iu/dl respect end year
compar iu/dl iu/dl respect end year
unrat announc valrox piii trial result met criteria regulatori submiss may
report interim data phase trial valrox patient
receiv dose vg/kg valrox data report april cut-off patient
reach week post-treat
result show median abr mean abr reduct baselin mean median
fviii level iu/dl iu/dl respect note portion manag call
level lower seen equival time point patient receiv dose
phase i/ii trial furthermor patient never achiev fviii level iu/dl
patient resum prophylact therapi
patient evalu april reach fviii level iu/dl greater addit patient
reach level subsequ data cut-off patient reach level iu/dl greater fda
pre-specifi criterion regulatori submiss thu biomarin plan meet fda ema review
data announc time regulatori file
ortx unrat announc world-wide licens agreement sr-tiget privat gt mps-i may
orchard announc acquir world-wide right ex vivo autolog hematopoiet
stem cell gt mucopolysaccharidosi type mp develop sr-tiget
mp gt sever therapi develop collabor orchard sr-
tiget also includ metachromat leukodystrophi mld wiskott-aldrich syndrom transfusion-
ortx unrat report result provid busi updat may
etherna immunotherapi privat present data trimixdc-mel studi cimt may
unrat announc azn unrat discontinu collabor except may
unrat announc licens nci t-cell receptor target neoantigen cancer may
freelin tx privat present preclin data aav-bas gt fabri diseas may
uc berkeley receiv crispr patent control repress activ gene may
unrat announc appoint dr pascal touchon presid ceo may
vor biopharma privat publish data gene-edit hsc murin model aml may
neutral announc expans gt collabor upenn may
amicu announc expans gt collabor dr jame wilson lab univers
pennsylvania term agreement amicu invest mm per year year upenn gt
program possibl extens
accord dr wilson agreement signific step forward creat world class industry-academia gene
therapi partnership rare diseas
collabor previous consist program rare lysosom diseas pomp diseas fabri diseas
defici lysosom diseas program expand includ neimann-pick type
mucopolysaccharidosi type iiib mp iiib next gener program mucopolysaccharidosi type iiia mp
iiia collabor also includ program addit rare diseas includ rett syndrom angelman
syndrom myoton dystrophi muscular dystrophi
buy announc appoint variou new leadership posit may
fcsc unrat receiv fda rmat design gt candid rdeb may
onc unrat announc collabor emerg health privat tavo may
unrat sponsor annual pyruv kinas defici day madrid spain may
bold buy announc replac chief medic offic senior vice presid may
page
neutral announc price mm public offer common stock may
buy announc complet enrol phase i/iia trial wamd may
etherna immunotherapi privat announc appoint ulrich platt cfo may
nih publish data effect cryopreserv variou car-t cell characterist may
buy announc dose patient phase trial aln-agt hypertens may
unrat announc collabor hgen unrat combo improv yescarta respons may
tx privat announc cross-licens agreement palett privat base edit may
blcm unrat present interim data phase i/ii trial car-t tx june
unrat announc initi phase ii portion phase i/ii trial solid tumor june
compani mention report
page
select catalyst genet medicin coverag
figur alnylam arrowhead dicerna krystal meira gtx expect initi trial
file ind rett syndrom
provid program updat phase i/ii valen trial crigler-najjar syndrom
select optim dose xlmtm
dcr-phxc initi long-term registr roll-ov studi ph
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
file ind cta pomp diseas
aro-aat initi phase ii/iii studi liver diseas
initi phase i/ii trial autosom recess congenit ichthyosi
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
initi trial malign
complet phase i/ii studi dystroph epidermolysi bullosa deb
top-lin phase ii data treat deb patient
complet ind-en studi diseas
dose patient phase studi mp
zolgensma anticip approv eu
lumasiran initi illuminate-b -c phase trial
givosiran complet nda applic file applic ahp
provid updat phase i/ii studi hemophilia
report phase i/ii data
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
page
select catalyst genet medicin coverag
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
report dose escal data pi/ii trial achm/xlrp
report preliminari data phase i/ii studi batten diseas
initi phase i/ii trial dmd
submit ema lhon
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
report interim efficaci readout phase oval trial ovarian cancer
xlrp report interim data expans arm phase i/ii trial xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
initi phase trial dystroph epidermolysi bullosa deb
file ind ornithin transcarbamylas over-the-counter defici
provid initi data phase trial gangliosidosi
axo-aav-opmd initi clinic trial opmd phase specifi
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
initi phase i/ii trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
updat dose escal pi/ii ignit trial dmd
zolgensma complet strong phase trial pre-symptomat sma type
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
initi phase i/ii studi best diseas
 file ind al huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
figur alnylam/mdco meira gtx nightstar solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
initi phase dose escal studi danon diseas
initi phase i/ii trial leukocyt adhes deficiency-i
initi phase trial recess dystroph epidermolysi bullosa
begin patient dose phase trial
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valrox present full piii top-line data hem
valrox submit bla pend fda feedback hemophilia
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
initi phase studi pyruv kinas defici pkd
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
initi phase i/ii trial adult phenylketonuria
rituximab report preliminari phase cohort expans data r/r nhl
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
micro-dystrophin initi confirmatori trial commerci materi dmd
initi phase trial multipl myeloma
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end may vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm gensight genet therapytickerratingccm ptupsideclosechang changemc mm translat gene editingtickerratingccm ptupsideclosechang changemc mm homolog pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap timevygr cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrated/nr name model current market
cap refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrated/nr name rgl model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrated/nr name model current market
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
